



ASX release

20 November 2012

## **SphygmoCor XCEL receives US FDA clearance**

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor® system which noninvasively measures central aortic blood pressures and arterial stiffness, announced today that it has received US Food and Drug Administration (FDA) clearance to market its new SphygmoCor XCEL system in the USA. The application for FDA clearance was filed in July 2012.

Duncan Ross, AtCor Medical CEO said, “This is an important step forward for AtCor, as it paves the way for us to sell XCEL systems in the valuable US clinical practice market, which is also our largest potential market. Importantly, the XCEL system is much simpler to use and provides invaluable data for clinicians to properly manage patients with hypertension and other cardiovascular related diseases.”

The SphygmoCor XCEL was introduced in the US at the American Society of Nephrology conference in San Diego earlier this month. It has been tailored for use by medical specialists in fields including cardiology, hypertension, nephrology (renal or kidney disease) and endocrinology (diabetes).

The system is already available for sale in Europe, Australia, and four Asian markets including India. The company plans to file applications for regulatory approval to sell into additional markets during the current financial year.

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 600 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact  
(AtCor):*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO  
+61 (2) 8815 8811

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)